Stefani S, Russo G, Pellegrino M B, Mezzatesta M L, Cocuzza C, Nicoletti G
Institute of Microbiology, University of Catania, Italy.
J Chemother. 1990 Feb;2(1):26-30. doi: 10.1080/1120009x.1990.11738976.
The ampicillin/sulbactam combination is one of several such drug combinations of a beta-lactam and suicide inhibitor having a wide spectrum of activity. These characteristics induced us to evaluate the in vitro activity of this combination towards 54 strains of Haemophilus sp. (38 beta-lactamase producers) and 20 strains of Branhamella catarrhalis (16 beta-lactamase producers). All strains were isolated from sputum, sinusal aspiration and tympanocentesis. In the case of Haemophilus sp beta-lactamase producers, minimal inhibitory concentrations of ampicillin were reduced 8 times by the use of the inhibitor; good results were also obtained for B. catarrhalis. Haemophilus influenzae, B. catarrhalis together with Streptococcus pneumoniae are recognized as the major pathogens involved in upper respiratory tract infections. The increasing frequency of beta-lactamase producing strains has impaired the use of aminopenicillins. The combination of an inhibitor and beta-lactam restore the activity of the latter, suggesting that this combination can serve as first choice in therapy.
氨苄西林/舒巴坦组合是几种具有广泛活性的β-内酰胺类与自杀性抑制剂的药物组合之一。这些特性促使我们评估该组合对54株嗜血杆菌属菌株（38株产β-内酰胺酶菌株）和20株卡他布兰汉菌（16株产β-内酰胺酶菌株）的体外活性。所有菌株均从痰液、鼻窦穿刺液和鼓膜穿刺液中分离得到。对于产β-内酰胺酶的嗜血杆菌属菌株，使用抑制剂后氨苄西林的最低抑菌浓度降低了8倍；对卡他布兰汉菌也取得了良好效果。流感嗜血杆菌、卡他布兰汉菌与肺炎链球菌一起被认为是上呼吸道感染的主要病原体。产β-内酰胺酶菌株频率的增加损害了氨基青霉素的使用。抑制剂与β-内酰胺的组合恢复了后者的活性，表明该组合可作为治疗的首选。
